Trimedat

Phase 1Small molecule

VValenta Pharm JSC

Trimedat is one of 27 small molecule programs targeting Oral. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

OralRecruiting

OralPhase 1

Recruiting

Competition

Competitive Landscape

50 competitors in Oral

#DrugCompanyPhaseTrials

Vepesid

AAvyxa

Phase 2

1 2

Marinol

Jazz Pharmaceuticals

Phase 1

2 3

GTX-104

GGrace Therapeutics Inc.

Phase 3

1 4

SHR-3167

JJiangsu HengRui Medicine Co., Ltd.

Phase 2

1 5

Pitressin

AAultman Health Foundation

Preclinical

1 6

Nubain

AAultman Health Foundation

Preclinical

1 7

DRSP/EE

Vertex Pharmaceuticals

Phase 1

1 8

VX-407

Vertex Pharmaceuticals

Phase 1

1 9

AB-101

AArtiva Biotherapeutics, Inc.

Phase 1

1 10

Gas-X

PPortuguese Oncology Institute, Coimbra

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Recruiting

Oral

NCT07421011

Clinical

Trials by Indication[1]

Oral1 trial

Pharmacokinetics, Bioequivalence, and Safety Study of Trimedat® 76,95 mg Orally Disintegrating Tablets and Trimedat® 100 mg Tablets in Healthy Volunteers.

Recruiting·VValenta Pharm JSC·Phase 1·NCT07421011·36 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Trimedat. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Trimedat compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Trimedat. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Valenta Pharm JSC company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: VValenta Pharm JSC

Trimedat

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Oral1 trial

References

Drug Info

Quick Facts

Related News